Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hong

Showing results (171-180 of 273) with videos related to

Pageof 28
Sort By:
Oncotarget|May 6, 2016
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experienceMing-Mo Hou, Zhijie Wang, Filip Janku, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2016
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancersMuhammad R Khawaja, Alpa M Nick, Vinu Madhusudanannair, et al.
British Journal of Cancer|March 20, 2018
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trialMichael L Maitland, Sarina Piha-Paul, Gerald Falchook, et al.
Cancer Science|November 29, 2019
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohortsYung-Jue Bang, Wu-Chou Su, Martin Schuler, et al.
Bioorganic Chemistry|February 24, 2021
Synthesis and biological evaluation of pentacyclic triterpenoid derivatives as potential novel antibacterial agentsPanpan Wu, Borong Tu, Jinfeng Liang, et al.
Oncotarget|May 8, 2018
Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutationsNeeta Somaiah, Hannah C Beird, Andrea Barbo, et al.
Oncotarget|July 16, 2016
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenonKanwal Raghav, Van Morris, Chad Tang, et al.
RSC Chemical Biology|January 5, 2024
Design, synthesis and modelling of photoreactive chemical probes for investigating target engagement of plasmepsin IX and X in <i>Plasmodium falciparum</i>Monika Lisauskaitė, Gemma L Nixon, Christopher M Woodley, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 19, 2018
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With ImmunotherapyChristine M Parseghian, Madhavi Patnana, Priya Bhosale, et al.
Oncotarget|October 4, 2018
Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancerYudong Wang, Zhijie Wang, Sarina Piha-Paul, et al.
Pageof 28

Showing results (171-180 of 273) with videos related to

Sort By:
Pageof 28
Oncotarget|May 6, 2016
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experienceMing-Mo Hou, Zhijie Wang, Filip Janku, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2016
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancersMuhammad R Khawaja, Alpa M Nick, Vinu Madhusudanannair, et al.
British Journal of Cancer|March 20, 2018
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trialMichael L Maitland, Sarina Piha-Paul, Gerald Falchook, et al.
Cancer Science|November 29, 2019
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohortsYung-Jue Bang, Wu-Chou Su, Martin Schuler, et al.
Bioorganic Chemistry|February 24, 2021
Synthesis and biological evaluation of pentacyclic triterpenoid derivatives as potential novel antibacterial agentsPanpan Wu, Borong Tu, Jinfeng Liang, et al.
Oncotarget|May 8, 2018
Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutationsNeeta Somaiah, Hannah C Beird, Andrea Barbo, et al.
Oncotarget|July 16, 2016
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenonKanwal Raghav, Van Morris, Chad Tang, et al.
RSC Chemical Biology|January 5, 2024
Design, synthesis and modelling of photoreactive chemical probes for investigating target engagement of plasmepsin IX and X in <i>Plasmodium falciparum</i>Monika Lisauskaitė, Gemma L Nixon, Christopher M Woodley, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 19, 2018
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With ImmunotherapyChristine M Parseghian, Madhavi Patnana, Priya Bhosale, et al.
Oncotarget|October 4, 2018
Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancerYudong Wang, Zhijie Wang, Sarina Piha-Paul, et al.
Pageof 28